Systemic treatment of hepatocellular carcinoma. An EASL position paper

Hepatology

Introduction to the Liver Imaging Reporting and Data System (LI-RADS) for hepatocellular carcinoma

Clin Gastroenterol Hepatol.

Tang A, Singal AG, Mitchell DG, Hecht EM, Fowler KJ, Kulik L, Parikh ND, Kono Y, Sirlin CB

doi: 10.1016/j.cgh.

Further Publications

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Lancet Gastroenterol Hepatol

Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V

doi: 10.1016/S2468-1253(21)00110-2

Hepatology

Hepatocellular carcinoma tumour volume doubling time: a systemic review and meta-analysis

Gut.

Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B, Marrero J, Parikh N, Singal AG

doi: 10.1136/gutjnl-2020-321040.

HepatitisHepatology

Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease

Am J Gastroenterol.

Chan TT, Chan WK, Wong GL, Chan AW, Nik Mustapha NR, Chan SL, Chong CC, Mahadeva S, Shu SS, Lai PB, Chan HL, Wong VW

doi: 10.14309/ajg.0000000000000588.

HepatitisHepatology

Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis

J Viral Hepat.

Masetti C, Lionetti , Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'Unto C, Francioso S, Brega A, Montalbano M, Visco-Comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'Offizi G, Gasbarrini A, De Santis A, Angelico M

doi: 10.1111/jvh.12982.

Hepatology

Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center

J Hepatocell Carcinoma

Karbeyaz F, Kissling S, Jaklin PJ, Bachofner J, Brunner B, Müllhaupt B, Winder T, Mertens JC, Misselwitz B, von Felten S, Siebenhüner AR

doi: 10.2147/JHC.S289955

HepatitisHepatology

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

J Hepatol.

Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A

doi: 10.1016/j.jhep.2018.03.009.

Gastrointestinal Cancer

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

J Clin Oncol

Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F

doi: 10.1200/JCO.21.00163

Gastrointestinal CancerHepatology

Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection

J Hepatol.

Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Reggiani MLB, Cucchetti A, Cescon M, Festi D

doi: 10.1016/j.jhep.2018.10.022.

Related content

Introduction to the Liver Imaging Reporting and Data System (LI-RADS) for hepatocellular carcinoma

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Hepatocellular carcinoma tumour volume doubling time: a systemic review and meta-analysis

Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease

Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis

Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection